{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:28:03Z","timestamp":1788305283273,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.canlet.2023.216103","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T12:07:37Z","timestamp":1676635657000},"page":"216103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia"],"prefix":"10.1016","volume":"558","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-1549","authenticated-orcid":false,"given":"Wenjian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216103_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-017-0505-0","article-title":"Recent developments in immunotherapy of acute myeloid leukemia","volume":"10","author":"Lichtenegger","year":"2017","journal-title":"J. Hematol. Oncol.J Hematol Oncol."},{"key":"10.1016\/j.canlet.2023.216103_bib2","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2023.216103_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.002","article-title":"Cellular therapy for acute myeloid Leukemia - current status and future prospects","volume":"37","author":"Hansrivijit","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.canlet.2023.216103_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216103_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216103_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.canlet.2023.216103_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2023.216103_bib8","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2023.216103_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2023.216103_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216103_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216103_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216103_bib13","doi-asserted-by":"crossref","first-page":"e1274","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.canlet.2023.216103_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol.J Hematol Oncol."},{"key":"10.1016\/j.canlet.2023.216103_bib15","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2023.216103_bib16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/leu.2013.18","article-title":"Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells","volume":"27","author":"Arndt","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2023.216103_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14728222.2014.909413","article-title":"The role of CD33 as therapeutic target in acute myeloid leukemia","volume":"18","author":"Walter","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2023.216103_bib18","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216103_bib19","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2023.216103_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri2073","article-title":"Prospects for the use of NK cells in immunotherapy of human cancer","volume":"7","author":"Ljunggren","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216103_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","article-title":"Natural killer cell cytotoxicity: how do they pull the trigger?","volume":"128","author":"Topham","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2023.216103_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2023.216103_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2023.216103_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-8885-3_6","article-title":"Isolation, expansion, and characterization of natural killer cells and their precursors as a tool to study cancer immunosurveillance","volume":"1884","author":"Parodi","year":"2019","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"10.1016\/j.canlet.2023.216103_bib25","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216103_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2567.2007.02757.x","article-title":"Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques","volume":"124","author":"Choi","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2023.216103_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2023.216103_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.0105-2896.2010.00908.x","article-title":"Cytotoxic and non-cytotoxic roles of the CTL\/NK protease granzyme B","volume":"235","author":"Afonina","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2023.216103_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216103_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.leu.2403737","article-title":"Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy","volume":"19","author":"Mejst\u0159\u00edkov\u00e1","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2023.216103_bib31","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216103_bib32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216103_bib33","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216103_bib34","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216103_bib35","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2023.216103_bib36","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352300054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352300054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:07:30Z","timestamp":1759594050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352300054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"alternative-id":["S030438352300054X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216103","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.14.516308","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216103"}}